View More Recent Stories

Aug 12, 2024 06:52AM Pacira Pharmaceuticals (PCRX) PT Lowered to $39 at H.C. Wainwright
Aug 12, 2024 06:43AM RBC Capital Downgrades Pacira Pharmaceuticals (PCRX) to Sector Perform
Aug 12, 2024 04:05AM Raymond James Downgrades Pacira Pharmaceuticals (PCRX) to Market Perform
Aug 12, 2024 02:26AM JPMorgan Downgrades Pacira Pharmaceuticals (PCRX) to Underweight
Aug 12, 2024 02:25AM Piper Sandler Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
Aug 9, 2024 03:23PM Pacira BioSciences (PCRX) Halted on Volatility, Down 12.6%
Aug 9, 2024 03:23PM Pacira BioSciences (PCRX) Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Aug 1, 2024 03:59PM Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
Jul 31, 2024 06:24AM Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
Jul 30, 2024 05:26PM Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance
Jul 10, 2024 04:20PM Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL (PCRX)
Jul 3, 2024 07:16AM Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX)
Jul 3, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
Jul 3, 2024 04:03AM Barclays Downgrades Pacira Pharmaceuticals (PCRX) to Equalweight
Jul 2, 2024 11:45AM RBC Capital on Pacira Pharmaceuticals (PCRX): 'regulatory approval of the generic form is just one piece of a larger puzzle'
Jul 2, 2024 11:40AM Truist Securities Defending Pacira Pharmaceuticals (PCRX): 'Knee Jerk Reaction Overdone As We See Limited Path For Generic To Launch Despite Approval'
Jul 2, 2024 11:02AM Pacira BioSciences (PCRX): Patent Infringement Suit vs eVenus is Still Pending
Jun 13, 2024 11:57AM Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
View More Recent Stories